FOR IMMEDIATE RELEASE: 2020/5/13

M3, Inc.
M3i, Inc.
TamaBio Co., Ltd.

Gunze Group to Distribute Seeds Rocket Product Durabeam™
~ Increased Presence in Neurosurgical Therapy Area ~

M3 Inc. (Headquarter: Tokyo, Japan; CEO: Itaru Tanimura; URL: https://corporate.m3.com/; “M3,” below) has reached an agreement with both GUNZE LIMITED (Headquarter: Osaka, Japan; CEO: Atsushi Hirochi; “Gunze,” below) and its subsidiary Medical U&A, Inc. (Headquarter: Osaka, Japan; CEO: Shojiro Matsuda; “Medical U&A,” below), for Medical U&A to launch distribution of Durabeam™ artificial dura mater product belonging to TamaBio Co., Ltd (Headquarters: Tokyo, Japan; CEO: Makoto Sawada; “TamaBio” below), a subsidiary of M3 established in April 2016.

Background

TamaBio was established in April 2016 as a part of the M3 Seeds Rocket business, with the objective to develop RIKEN’s unique technology in polymer resin processing into a practical base technology and to achieve the earliest provision of its developed products to patients. Durabeam™ is an artificial dura mater developed using RIKEN’s polymer resin processing technology, and has received approval to manufacture and distribute the product as of September 2017.

Medical U&A was the first to distribute of Durawave™ in Japan upon approval by MHLW for manufacturing and distribution in April 2017. The product is an absorbable, non-suture artificial dura mater product that requires combined usage of a tissue sealant over the defective dura mater area.

Durabeam™, a non-absorbable artificial dura mater, has built a track record of performance in practice at over 30 medical sites of which were mainly university hospitals, and has been highly evaluated within the clinical scene since its approval in September 2017.

This collaboration between the two firms will add Durabeam™ to Medical U&A’s product line-up. The expected synergies from offering both absorbable and non-absorbable types of artificial dura maters will bring Medical U&A to the forefront of this market as a leading company contributing to the enhancement of QOL for patients.
Durabeam™ Product Features

Durabeam™ is a non-absorbable artificial dura mater which has received approval from the MHLW to manufacture and distribute the product as of September 2017. This product was created alongside feedback from field experts in order to overcome issues such as post-surgical infections and adhesions. Durabeam’s higher biocompatibility and shorter surgical procedure compared to existing products, is expected to reduce such risks.

Product Name: Durabeam™
Product Characteristics: High biocompatibility achieved through ion-beam irradiation of expanded polytetrafluoroethylene (ePTFE) sheets
Product Purpose: Cranial dura mater supplementation and substitution
Product Distribution: July 2020 (expected)
Product Manufacturer: TamaBio Co., Ltd

Through M3’s Seeds Rocket initiative, the subsidiary M3i, Inc. (Headquarter: Tokyo, CEO: Kazuhiro Umeda, “M3i” below) strives to meet unmet medical needs across the globe, and to contribute to society by developing drugs, medical devices and regenerative medicine that will be truly appreciated by patients, while simultaneously structuring an ecosystem that can support medical venture businesses, both domestic and overseas.

< Medical U&A Overview >

Founded: April 1986 (subsidiary of Gunze)
Headquarters: Osaka, Japan
CEO: Shojiro Matsuda
Business: Medical device distribution related to plastic surgery, neurosurgery, oral surgery, cosmetic surgery, pediatric surgery, cardiovascular surgery, dermatology, and others; private practice consulting, medical device development and distribution
Website: https://www.mua.co.jp/

< TamaBio Overview >

Founded: April 2016 (M3 subsidiary)
Headquarters: Tokyo, Japan
CEO: Makoto Sawada
Business: medical device development and distribution